| http://www.w3.org/ns/prov#value | - ing and other activities, the conduct, timing and results of pre-clinical and clinical studies of our product candidates, the adequacy of our capital resources and the availability of additional funding, uncertainties related to the timing of identifying and recruiting a new independent director, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commi
|
